News

Abide Therapeutics, Inc., a clinical-stage biopharmaceutical company founded by Scripps Research professors Benjamin Cravatt, PhD, and Dale Boger, PhD, will be acquired by the Danish pharmaceutical firm H. Lundbeck A/S (Lundbeck).

The U.S. Food and Drug Administration has approved tafamidis for the treatment of heart disease (cardiomyopathy) caused by mutant or wild-type transthyretin aggregation in adults.

Eleven students from high schools across Palm Beach County will join biomedical research laboratories at Scripps Research in Jupiter, Florida this summer as part of the institute’s 15th annual high school student internship program.

Scientists at Scripps Research have developed an experimental vaccine that may one day help treat addiction to fentanyl, a highly potent opioid linked to an epidemic of overdoses and fatalities in recent years.

There may be reason to treat severe neurodevelopmental disorders at any stage of life once options become available, a new study of SYNGAP1 related autism suggests.

Researchers at the Scripps Research Translational Institute have launched a new digital research platform called POWERMOM that enables pregnant women anywhere in the United States to contribute their health information to the study using a smartphone app.

The American Academy of Arts and Sciences, one of the world’s most prestigious honor societies, has named Scripps Research chemist Jin-Quan Yu, PhD, as an elected member of its 2019 class. Yu is known globally for his groundbreaking work in the field of organic synthetic chemistry.

Brenner devoted his career to conducting groundbreaking basic research. His many contributions to molecular biology led to his being co-awarded the Nobel Prize in Physiology or Medicine in 2002.

In a study with the National Institute on Drug Abuse, scientists at Scripps Research discovered that oxytocin blocked enhanced drinking in alcohol-dependent rats, concluding that targeting the oxytocin system may be a successful pharmaceutical approach for treating alcohol-use disorder.

Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a progressive and often fatal disease.

New research will now make it possible to screen drug candidates more reliably and investigate the root cause of Parkinson’s disease.

Charity Navigator awards Scripps Research four stars for exceeding industry standards in financial health, accountability and transparency.

Scientists find evidence that RNA and DNA could have arisen from the same set of precursor molecules before life evolved four billion years ago.

Currently there is no treatment for myotonic dystrophy type 1. Now, researchers say they have made a potential drug that targets a disease-causing RNA at the root of the disease.  

The International AIDS Vaccine Initiative (IAVI) announced the start of a Phase I clinical trial to test a novel HIV vaccine candidate, an advance in vaccine design enabled by Scripps Research discoveries.

New method could enable faster study of strategies to combat age-related diseases.

New drugs for neurodegenerative and genetic disorders making their way to the marketplace.

Scientists at Scripps Research have found that they can reverse the desire to drink in alcohol-dependent rats—with the flip of a switch.

New book Deep Medicine released and garners significant media attention. Click to read more and review ongoing media coverage. 

In a breakthrough with applicability across many flu strains, researchers find a potential small molecule that mimics antibodies to treat disease.

For the last decade researchers have been developing a drug candidate that eases inflammation and protects brain cells from damage. Now, research shows another potential application: treating Alzheimer’s disease. 

In a New York Times op-ed, Eric Topol, MD, founder and director of Scripps Research Translational Institute, discusses the science of nutrition and the need for diet to be individualized.

Scripps Research assistant professor Luke Lairson, PhD, and colleagues have discovered a compound that potently and selectively kills the stem-like cells that make glioblastoma brain cancers so deadly.

Program supports workforce training recommended by Eric Topol, MD, in an independent review of the digital future of the National Health Service.